Specificity and Regulation of Casein Kinase-mediated Phosphorylation of Alpha-synuclein

Overview

Journal J Neuropathol Exp Neurol

Publisher Oxford University Press

Specialties Neurology
Pathology

Date 2008 May 3

PMID 18451726

Citations 126

Authors

Elisa A Waxman

Benoit I Giasson

Affiliations

Soon will be listed here.

Abstract

alpha-Synuclein (alpha-syn) is the major component of pathologic inclusions that characterize neurodegenerative disorders such as Parkinson disease, dementia with Lewy body disease, and multiple system atrophy. The present study uses novel phospho-specific antibodies to assess the presence and regulation of phosphorylated Ser87 and Ser129 in alpha-syn in human brain samples and in a transgenic mouse model of alpha-synucleinopathies. By immunohistochemistry, alpha-syn phosphorylated at Ser129, but not at Ser87, was abundant in alpha-syn inclusions. Under normal conditions, Ser129 phosphorylation, but not Ser87 phosphorylation, was detected at low levels in the soluble biochemical fractions in human alpha-syn transgenic mice and stably transfected cultured cells. Therefore, a role for Ser87 phosphorylation in alpha-synucleinopathies is unlikely, and in vitro assays showed that phosphorylation at this site would inhibit polymerization. In vitro studies also indicated that hyperphosphorylation of Ser129 alpha-syn in pathologic inclusions may be due in part to the intrinsic properties of aggregated alpha-syn to act as substrates for kinases but not phosphatases. Further studies in transgenic mice and cultured cells suggest that cellular toxicity, including proteasomal dysfunction, increases casein kinase 2 activity, which results in elevated Ser129 alpha-syn phosphorylation. These data provide novel explanations for the presence of hyperphosphorylated Ser129 alpha-syn in pathologic inclusions.

Citing Articles

Investigation of All Disease-Relevant Lysine Acetylation Sites in α-Synuclein Enabled by Non-canonical Amino Acid Mutagenesis.

Shimogawa M, Li M, Park G, Ramirez J, Lee H, Watson P bioRxiv. 2025; .

PMID: 39896484 PMC: 11785115. DOI: 10.1101/2025.01.21.634178.

Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson's disease.

Hallbeck M, Ekmark-Lewen S, Kahle P, Ingelsson M, Reyes J iScience. 2024; 27(12):111448.

PMID: 39720536 PMC: 11667178. DOI: 10.1016/j.isci.2024.111448.

α-Synuclein pathology as a target in neurodegenerative diseases.

Park H, Kam T, Dawson V, Dawson T Nat Rev Neurol. 2024; 21(1):32-47.

PMID: 39609631 DOI: 10.1038/s41582-024-01043-w.

Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.

Genetic modifiers of synucleinopathies-lessons from experimental models.

Lee R, Koh T Oxf Open Neurosci. 2024; 2:kvad001.

PMID: 38596238 PMC: 10913850. DOI: 10.1093/oons/kvad001.

References

Gong C, Grundke-Iqbal I, Damuni Z, Iqbal K . Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett. 1994; 341(1):94-8. DOI: 10.1016/0014-5793(94)80247-5. View

Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D . Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Lett. 2007; 581(24):4711-7. DOI: 10.1016/j.febslet.2007.08.067. View

Nishie M, Mori F, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T . Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. 2004; 107(4):292-8. DOI: 10.1007/s00401-003-0811-1. View

Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil K . Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem. 2004; 279(13):12924-34. DOI: 10.1074/jbc.M306390200. View

Pronin A, Morris A, Surguchov A, Benovic J . Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem. 2000; 275(34):26515-22. DOI: 10.1074/jbc.M003542200. View

Gong C, Singh T, Grundke-Iqbal I, Iqbal K . Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2B (calcineurin). J Neurochem. 1994; 62(2):803-6. DOI: 10.1046/j.1471-4159.1994.62020803.x. View

Lee G, Tanaka M, Park K, Lee S, Kim Y, Junn E . Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem. 2003; 279(8):6834-9. DOI: 10.1074/jbc.M312760200. View

Giasson B, Murray I, Trojanowski J, Lee V . A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2000; 276(4):2380-6. DOI: 10.1074/jbc.M008919200. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

10.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

11.

Pagano M, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J . Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004; 47(25):6239-47. DOI: 10.1021/jm049854a. View

12.

von Bohlen Und Halbach O . Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 2004; 318(1):163-74. DOI: 10.1007/s00441-004-0921-7. View

13.

Pagano M, Poletto G, Maira G, Cozza G, Ruzzene M, Sarno S . Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2006; 8(1):129-39. DOI: 10.1002/cbic.200600293. View

14.

McNaught K, Jackson T, JnoBaptiste R, Kapustin A, Olanow C . Proteasomal dysfunction in sporadic Parkinson's disease. Neurology. 2006; 66(10 Suppl 4):S37-49. DOI: 10.1212/wnl.66.10_suppl_4.s37. View

15.

Nakajo S, Shioda S, Nakai Y, Nakaya K . Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. Brain Res Mol Brain Res. 1994; 27(1):81-6. DOI: 10.1016/0169-328x(94)90187-2. View

16.

Greenbaum E, Graves C, Mishizen-Eberz A, Lupoli M, Lynch D, Englander S . The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem. 2005; 280(9):7800-7. DOI: 10.1074/jbc.M411638200. View

17.

Kahle P, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W . Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002; 3(6):583-8. PMC: 1084143. DOI: 10.1093/embo-reports/kvf109. View

18.

Sidhu A, Wersinger C, Vernier P . Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J. 2004; 18(6):637-47. DOI: 10.1096/fj.03-1112rev. View

19.

Tanaka Y, Engelender S, Igarashi S, Rao R, Wanner T, Tanzi R . Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 2001; 10(9):919-26. DOI: 10.1093/hmg/10.9.919. View

20.

Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H . Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004; 91(2):451-61. DOI: 10.1111/j.1471-4159.2004.02728.x. View